MA53924A - Modulateurs de l'expression d'apol1 - Google Patents

Modulateurs de l'expression d'apol1

Info

Publication number
MA53924A
MA53924A MA053924A MA53924A MA53924A MA 53924 A MA53924 A MA 53924A MA 053924 A MA053924 A MA 053924A MA 53924 A MA53924 A MA 53924A MA 53924 A MA53924 A MA 53924A
Authority
MA
Morocco
Prior art keywords
expression modulators
apol1 expression
apol1
modulators
expression
Prior art date
Application number
MA053924A
Other languages
English (en)
Inventor
Susan M Freier
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of MA53924A publication Critical patent/MA53924A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA053924A 2018-05-22 2019-05-21 Modulateurs de l'expression d'apol1 MA53924A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862674865P 2018-05-22 2018-05-22

Publications (1)

Publication Number Publication Date
MA53924A true MA53924A (fr) 2021-08-25

Family

ID=68613945

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053924A MA53924A (fr) 2018-05-22 2019-05-21 Modulateurs de l'expression d'apol1

Country Status (27)

Country Link
US (4) US10927377B2 (fr)
EP (1) EP3799570A4 (fr)
JP (3) JP7247227B2 (fr)
KR (2) KR20250153881A (fr)
CN (3) CN112423792B (fr)
AR (1) AR115416A1 (fr)
AU (2) AU2019274461B2 (fr)
BR (1) BR112020023436A2 (fr)
CA (1) CA3099750A1 (fr)
CL (1) CL2020003010A1 (fr)
CO (1) CO2020015377A2 (fr)
CR (1) CR20200631A (fr)
EA (1) EA202092748A1 (fr)
EC (1) ECSP20082339A (fr)
IL (2) IL316397A (fr)
JO (1) JOP20200291A1 (fr)
MA (1) MA53924A (fr)
MX (2) MX2020012497A (fr)
MY (1) MY200352A (fr)
NI (1) NI202000085A (fr)
PE (1) PE20211397A1 (fr)
PH (1) PH12020551995A1 (fr)
SG (1) SG11202011397QA (fr)
TW (2) TW202430638A (fr)
UA (1) UA128819C2 (fr)
WO (1) WO2019226611A1 (fr)
ZA (1) ZA202007537B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49076E1 (en) 2010-04-18 2022-05-17 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
IL316397A (en) 2018-05-22 2024-12-01 Ionis Pharmaceuticals Inc Modulators of APOL1 expression
CN113453760B (zh) 2018-12-17 2024-05-24 弗特克斯药品有限公司 Apol1抑制剂及其使用方法
AU2021213758A1 (en) 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
CA3183591A1 (fr) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Formes solides d'un inhibiteur d'apol1 et utilisation de celles-ci
CN116157393A (zh) 2020-06-12 2023-05-23 弗特克斯药品有限公司 Apol1的抑制剂及其用途
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
EP4573077A1 (fr) * 2022-08-19 2025-06-25 Maze Therapeutics, Inc. Inhibiteurs d'apol1 et procédés d'utilisation
WO2025242689A1 (fr) 2024-05-21 2025-11-27 Astrazeneca Ab Méthodes de traitement d'une maladie rénale médiée par apol1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082401A1 (en) 1994-12-15 2002-06-27 Yeda Research And Development Company Modulators of the function of FAS/APO1 receptors
US6833361B2 (en) * 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
WO2002028999A2 (fr) 2000-10-03 2002-04-11 Gene Logic, Inc. Profils d'expression genique dans les cellules granulocytaires
USH2191H1 (en) 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US20070054278A1 (en) 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
US20050171044A1 (en) 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
EP2397563A3 (fr) 2004-09-17 2012-07-18 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
EP1867338A1 (fr) 2006-05-30 2007-12-19 Université Libre De Bruxelles Composition pharmaceutique comprenant des apolipoprotéines
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
CA2739464C (fr) 2008-10-03 2020-03-31 Curna, Inc. Traitement de maladies liees a l'apolipoproteine a1 par l'inhibition d'un produit de la transcription antisens naturel de l'apolipoproteine a1
CN108042560A (zh) 2008-12-04 2018-05-18 库尔纳公司 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病
EP2470658A1 (fr) 2009-08-18 2012-07-04 Université Libre de Bruxelles Variants d'apolipoprotéine l-i et leur utilisation
CA2779830C (fr) 2009-11-13 2020-07-21 Avi Biopharma, Inc. Compose antiviral antisens et methode de traitement d'une infection par le virus grippal
JP6031356B2 (ja) 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
US9023355B2 (en) 2010-04-13 2015-05-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
US20120003644A1 (en) 2010-06-07 2012-01-05 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for determining predisposition to develop kidney diseases
EP2812433A4 (fr) * 2012-02-08 2016-01-20 Isis Pharmaceuticals Inc Méthodes et compositions permettant de moduler l'expression du facteur vii
WO2013177468A2 (fr) 2012-05-24 2013-11-28 Isis Pharmaceuticals, Inc. Procédés et compositions de modulation de l'expression de l'apolipoprotéine(a)
EP2920206A4 (fr) 2012-11-16 2016-07-06 Merck Sharp & Dohme Polypeptides apol1 modifiés
US10130632B2 (en) * 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
JP2016522675A (ja) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
GB201311057D0 (en) 2013-06-21 2013-08-07 Univ Greenwich Antisense oligonucleotide compositions
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2015136509A2 (fr) 2014-03-14 2015-09-17 Genesis Theranostix Korlatolt Felelossegu Tarsasag Cibles diagnostiques et thérapeutiques de la prééclampsie et d'autres complications étroitement associées à la grossesse
EP3119888B1 (fr) 2014-03-19 2021-07-28 Ionis Pharmaceuticals, Inc. Compositions permettant de moduler l'expression de l'ataxine 2
EP3020813A1 (fr) 2014-11-16 2016-05-18 Neurovision Pharma GmbH Oligonculéotides antisens en tant qu'inhibiteurs de la signalisation de TGF-R
TW201718010A (zh) 2015-06-19 2017-06-01 健臻公司 治療原發性局部節段性腎小球硬化症之方法
IL318703A (en) 2015-06-29 2025-03-01 Caris Science Inc Therapeutic oligonucleotides
SG10201913209WA (en) * 2015-09-24 2020-02-27 Ionis Pharmaceuticals Inc Modulators of kras expression
IL316397A (en) 2018-05-22 2024-12-01 Ionis Pharmaceuticals Inc Modulators of APOL1 expression

Also Published As

Publication number Publication date
AR115416A1 (es) 2021-01-13
UA128819C2 (uk) 2024-10-30
CN118127020A (zh) 2024-06-04
US10927377B2 (en) 2021-02-23
AU2025259982A1 (en) 2026-01-22
TW202016305A (zh) 2020-05-01
EP3799570A4 (fr) 2022-04-27
KR102874776B1 (ko) 2025-10-24
ECSP20082339A (es) 2021-02-26
MY200352A (en) 2023-12-21
CN112423792A (zh) 2021-02-26
MX2025003294A (es) 2025-05-02
WO2019226611A1 (fr) 2019-11-28
US20250066785A1 (en) 2025-02-27
BR112020023436A2 (pt) 2021-02-23
CA3099750A1 (fr) 2019-11-28
CL2020003010A1 (es) 2021-06-11
CR20200631A (es) 2021-02-10
MX2020012497A (es) 2021-02-15
JP2025013513A (ja) 2025-01-24
IL278785A (en) 2021-01-31
JP7645301B2 (ja) 2025-03-13
US11525136B2 (en) 2022-12-13
TW202430638A (zh) 2024-08-01
US20210079395A1 (en) 2021-03-18
CO2020015377A2 (es) 2020-12-21
CN118127019A (zh) 2024-06-04
US20230265428A1 (en) 2023-08-24
AU2019274461B2 (en) 2025-07-31
TWI841564B (zh) 2024-05-11
ZA202007537B (en) 2021-09-29
SG11202011397QA (en) 2020-12-30
US20190359981A1 (en) 2019-11-28
JP2021525084A (ja) 2021-09-24
IL278785B2 (en) 2025-03-01
IL316397A (en) 2024-12-01
JOP20200291A1 (ar) 2020-11-15
JP2023075283A (ja) 2023-05-30
EA202092748A1 (ru) 2021-04-19
JP7247227B2 (ja) 2023-03-28
PH12020551995A1 (en) 2021-09-06
AU2019274461A1 (en) 2021-01-14
PE20211397A1 (es) 2021-07-27
US12168766B2 (en) 2024-12-17
IL278785B1 (en) 2024-11-01
CN112423792B (zh) 2024-04-23
KR20210011981A (ko) 2021-02-02
NI202000085A (es) 2021-03-11
EP3799570A1 (fr) 2021-04-07
KR20250153881A (ko) 2025-10-27

Similar Documents

Publication Publication Date Title
MA53924A (fr) Modulateurs de l'expression d'apol1
EP3853365A4 (fr) Modulateurs de l'expression de pnpla3
EP3768854A4 (fr) Modulation de l'expression de hsd17b13
EP3735685A4 (fr) Panneau d'affichage
EP3906026A4 (fr) Inhibiteurs irréversibles de l'interaction ménine-mll
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3750149C0 (fr) Panneau d'affichage
EP3798719A4 (fr) Panneau d'affichage
EP3692028A4 (fr) Inhibition de la peptidase 30 spécifique de l'ubiquitine
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
EP3926701A4 (fr) Panneau d'affichage
EP3672650A4 (fr) Hydrogel pour l'ingénierie tissulaire et la bio-impression
MA53721A (fr) Modulateurs de la monoacylglycérol lipase
EP3756061A4 (fr) Mécanismes de levage d'affichage
MA54386A (fr) Modulateurs de trex1
MA51645A (fr) Modulateurs de l'expression de dnm2
EP3605180A4 (fr) Objectif d'magerie
IL268905B (en) Phage therapy
EP3506863A4 (fr) Applicateurs d'implant
EP3482698A4 (fr) Instrument d'hémostase
EP3982415A4 (fr) Panneau d'affichage
MA53722A (fr) Modulateurs de la monoacylglycérol lipase
MA51795A (fr) Oligonucléotides pour moduler l'expression de tmem106b
EP3733177A4 (fr) Composition pour la protection de la cornée
IL286663A (en) Hydrogel